Gene Silencing of FANCF Potentiates the Sensitivity to Mitoxantrone through Activation of JNK and p38 Signal Pathways in Breast Cancer Cells

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Li, Yanlin ^a   Zhao, Lin ^a   Sun, Haigang ^a   Yu, Jiankun ^a   Li, Na ^a   Liang, Jingwei ^a   Wang, Yan ^a   He, Miao ^a   Bai, Xuefeng ^a   Yu, Zhaojin ^a   Zheng, Zhihong ^a   Mi, Xiaoyi ^a   Wang, Enhua ^a   Wei, Minjie ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BRCA1 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CASPASE 6; CASPASE 9; FANCONI ANEMIA GROUP F PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOXANTRONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; SHORT HAIRPIN RNA; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CHROMOSOME; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVATION; FANCF GENE; GENE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MITOCHONDRION; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FANCONI ANEMIA COMPLEMENTATION GROUP F PROTEIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MITOCHONDRIA; MITOXANTRONE; NEOPLASM PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION; UP-REGULATION;

EID: 84865479089     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044254     Document Type: Article

References (53)

1. Niedernhofer LJ, Lalai AS, Hoeijmakers JH, (2005) Fanconi anemia (cross)linked to DNA repair. Cell 123: 1191-1198.
2. Auerbach AD, (2009) Fanconi anemia and its diagnosis. Mutat Res 668: 4-10.
3. Alan D, (2010) The Fanconi Anemia and Breast Cancer Susceptibility Pathways. N Engl J Med 362: 1909-1919.
4. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, et al. (2010) Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 42: 406-409.
5. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, et al. (2011) Mutations of the SLX4 gene in Fanconi anemia. Nat Genet 43: 142-146.
6. Stoepker C, Hain K, Schuster B, Hilhorst-Hofstee Y, Rooimans MA, et al. (2011) SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet 43: 138-141.
7. Meetei AR, Sechi S, Wallisch M, Yang D, Young MK, et al. (2003) A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. Mol Cell Biol 23: 3417-3426.
8. Tumini E, Plevani P, Muzi-Falconi M, Marini F, (2011) Physical and functional crosstalk between Fanconi anemia core components and the GINS replication complex. DNA Repair (Amst) 10: 149-158.
9. Alpi AF, Patel KJ, (2009) Monoubiquitylation in the Fanconi anemia DNA damage response pathway. DNA Repair (Amst) 8: 430-435.
10. Bogliolo M LA, Callén E, Castellà M, Cappelli E, Ramírez MJ, et al. (2007) Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability. EMBO J 26: 1340-1351.
11. Lyakhovich A SJ, (2007) New Roads to FA/BRCA Pathway. Cell Cycle 6: 1019-1023.
12. Lim SL, Smith P, Syed N, Coens C, Wong H, et al. (2008) Promoter hypermethylation of FANCF and outcome in advanced ovarian cancer. Br J Cancer 98: 1452-1456.
13. Wang Z LM, Lu S, Zhang Y, Wang H, (2006) Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol Ther 5: 5.
14. Tischkowitz M, Ameziane N, Waisfisz Q, De Winter JP, Harris R, et al. (2003) Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br J Haematol 123: 469-471.
15. Narayan G A-PH, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, et al. (2004) Promoter Hypermethylation of FANCF: Disruption of Fanconi Anemia-BRCA Pathway in Cervical Cancer. Cancer Res 64: 2994-2997.
16. Neveling K, Kalb R, Florl AR, Herterich S, Friedl R, et al. (2007) Disruption of the FA/BRCA pathway in bladder cancer. Cytogenet Genome Res 118: 166-176.
17. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, et al. (2004) Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23: 1000-1004.
18. Chen CC, Taniguchi T, D'Andrea A, (2007) The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. Journal of Molecular Medicine 85: 497-509.
19. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS, (2005) The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 106: 698-705.
20. Chirnomas D TT, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, et al. (2006) Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther 5: 952-961.
21. AD DA, (2003) The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle 2: 290-292.
22. Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, et al. (2012) Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A 109: 3024-3029.
23. Casado JA, Rio P, Marco E, Garcia-Hernandez V, Domingo A, et al. (2008) Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther 7: 1309-1318.
24. Salerno S, Da Settimo F, Taliani S, Simorini F, La Motta C, et al. (2010) Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs. Curr Med Chem 17: 4270-4290.
25. Hazlehurst LA AR, Emmons M, Boulware D, Beam CA, Sullivan DM, et al. (2006) Cell Adhesion to Fibronectin (CAM-DR) Influences Acquired Mitoxantrone Resistance in U937 Cells. Cancer Res 66: 2338-2345.
26. Kumpulainen EJ, Hirvikoski PP, Johansson RT, (2008) Long-term outcome of adjuvant chemotherapy cyclophosphamide, mitoxantrone, and fluorouracil in women with breast cancer. Acta Oncologica 47: 120-123.
27. Cleator SJ, Makris A, Ashley SE, Lal R, Powles TJ, (2005) Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol 16: 267-272.
28. Kim J, Lee J, Chang E, Suh K, Lee C, et al. (2011) Prognostic Factors in Patients with Stage II/III Breast Cancer Treated with Adjuvant Extension of Neoadjuvant Chemotherapy: A Retrospective Cohort Study with Ten-Years of Follow-Up Data. J Breast Cancer 14: 39-45.
29. Follin-Arbelet V, Hofgaard PO, Hauglin H, Naderi S, Sundan A, et al. (2011) Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model. BMC Cancer 11: 301.
30. Peng H, Dong Z, Qi J, Yang Y, Liu Y, et al. (2009) A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy. PLOS ONE 4: e5676.
31. Singh NP, McCoy MT, Tice RR, Schneider EL, (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175: 184-191.
32. Klaude M, Eriksson S, Nygren J, Ahnstrom G, (1996) The comet assay: mechanisms and technical considerations. Mutat Res 363: 89-96.
33. Kanagasabai R, Krishnamurthy K, Druhan LJ, Ilangovan G, (2011) Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells. J Biol Chem 286: 33289-33300.
34. Briot D, Mace-Aime G, Subra F, Rosselli F, (2007) Aberrant activation of stress-response pathways leads to TNF- oversecretion in Fanconi anemia. Blood 111: 1913-1923.
35. Liu J, Lin A, (2005) Role of JNK activation in apoptosis: a double-edged sword. Cell Res 15: 36-42.
36. Jang JY, Jeon YK, Choi Y, Kim CW, (2010) Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression. Mol Cancer 9: 262.
37. Mooney LM, Al-Sakkaf KA, Brown BL, Dobson PRM, (2002) Apoptotic mechanisms in T47D and MCF-7 human breast cancer cells. British Journal of Cancer 87: 909-917.
38. Janicke RU, (2009) MCF-7 breast carcinoma cells do not express caspase-3. Breast Cancer Res Treat 117: 219-221.
39. Kachnic LA, Li L, Fournier L, Ferraiolo N, Dahm-Daphi J, et al. (2011) FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons. Cancer Lett 305: 86-93.
40. Evseenko DA, Paxton JW, Keelan JA, (2007) Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab Dispos 35: 595-601.
41. Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY, Ng DC, (2010) c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges. Biochim Biophys Acta 1804: 463-475.
42. Stadheim TA, Kucera GL, (2002) c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells. Leuk Res 26: 55-65.
43. Bitomsky N, Hofmann TG, (2009) Apoptosis and autophagy: Regulation of apoptosis by DNA damage signalling- roles of p53, p73 and HIPK2. FEBS Journal 276: 6074-6083.
44. Tang D, Lotze MT, Kang R, Zeh HJ, (2011) Apoptosis promotes early tumorigenesis. Oncogene 30: 1851-1854.
45. Sabisz M, Wesierska-Gadek J, Skladanowski A, (2010) Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints. Biochem Pharmacol 79: 1387-1397.
46. Nam C, Yamauchi H, Nakayama H, Doi K, (2006) Etoposide induces apoptosis and cell cycle arrest of neuroepithelial cells in a p53-related manner. Neurotoxicol Teratol 28: 664-672.
47. Qi X, Chang Z, Song J, Gao G, Shen Z, (2011) Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin. Anticancer Drugs 22: 556-562.
48. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM, (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234.
49. Bakker ST, van de Vrugt HJ, Visser JA, Delzenne-Goette E, van der Wal A, et al. (2011) Fancf-deficient mice are prone to develop ovarian tumours. The Journal of Pathology: n/a-n/a.
50. Nitiss JL, (2009) DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 9: 327-337.
51. Rothfuss A, Grompe M, (2003) Repair Kinetics of Genomic Interstrand DNA Cross-Links: Evidence for DNA Double-Strand Break-Dependent Activation of the Fanconi Anemia/BRCA Pathway. Molecular and Cellular Biology 24: 123-134.
52. Ashworth A, (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26: 3785-3790.
53. Houlbrook S, Addison CM, Davies SL, Carmichael J, Stratford IJ, et al. (1995) Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 72: 1454-1461.